---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-010370"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T14:58:59.666751+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics cuts 80% workforce, begins strategic review after FDA setback for uproleselan

## Summary
- FDA feedback requires an additional clinical trial for uproleselan in R/R AML; regulatory path uncertain.
- Workforce reduced by 26 employees (~80%); expects $3.6M in severance charges in Q3 2024.
- CMO Dr. Edwin Rock departs July 31; will receive 12 months' base salary severance and consulting deal.
- Cash and equivalents ~$31.3M as of March 31; restructuring extends cash runway into Q2 2025.
- Engaged Lucid Capital Markets to explore strategic alternatives including sale, merger, or licensing.

## SEC filing metadata
- accession: 0001558370-24-010370
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837024010370/0001558370-24-010370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837024010370/glyc-20240724x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-010370
- JSON: https://secwatch.observer/filing/0001558370-24-010370.json
- Plain text: https://secwatch.observer/filing/0001558370-24-010370.txt

## Key facts
- Executive change
  Dr. Edwin Rock departed as Chief Medical Officer at CRESCENT BIOPHARMA, INC..
  - Action: departed
  - Role: Chief Medical Officer
  source text: the employment of Dr. Edwin Rock, the Company’s Chief Medical Officer, will end on July 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837024010370/0001558370-24-010370-index.htm
- Restructurings & Charges
  CRESCENT BIOPHARMA, INC. announced a restructuring with charges of approximately $3.6 million (reduction in the Company's workforce by 26 employees, or approximately 80% of its headcount).
  - Type: restructuring
  - Charge: approximately $3.6 million
  - Headcount: reduction in the Company's workforce by 26 employees, or approximately 80% of its headcount
  source text: in connection with the streamlined operating plan approved by the Board, on July 24, 2024, the authorized officers of the Company committed the Company to a corporate restructuring that includes a reduction in the Company's workforce by 26 employees, or approximately 80% of its headcount. The Company expects to substantially complete the reduction by July 31, 2024. The Company anticipates recognizing approximately $3.6 million in total charges in connection with the headcount reduction
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837024010370/0001558370-24-010370-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.